Also found in: Wikipedia.


An oral prostacyclin PGI2 analogue with vasodilator, antiplatelet, and cytoprotective effects, used to manage pulmonary arterial hypertension. Beraprost improves exercise capacity and symptoms in NYHA-functional class-II and -III patients with PAH and, in particular, in those with primary pulmonary hypertension.

Adverse effects
Headache, facial flushing, vasodilation.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.


Epoprostenol A formulation of prostacyclin in trials for pulmonary vascular disease 2º to treatment with diet drugs
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Sales of Beraprost sodium tablets amounted to approximately RMB112 million, an increase of approximately 12.8% as compared with the same period last year.
He had been taking clopidogrel, aspirin, and beraprost following infrarenal abdominal aortic aneurysm repair since 2013.
[PGI.sub.2] itself and several IP agonists such as beraprost and iloprost are now used to treat pulmonary arterial hypertension, chronic arterial occlusion, and other diseases in which the blood vessels are constricted and blood cannot flow to the tissues.
Beraprost and ticlopidine inhibit small aggregate formation in BRVO patients and may represent effective antiplatelet treatments [189].
The same group also found that the prostaglandin I2 analogue beraprost sodium could also reverse the effects of ioversol on caspases and Bax/Bcl-2 [56] by phosphorylation of the cAMP-responsive element binding protein (CREB) via a PKA-dependent mechanism.
For example, Beraprost, an oral prostaglandin is proving helpful in extending exercise limits (Harvey, S., 2002).
They exceed the improvements reported for other conventional PAD drug therapies including pentoxifylline, cilostazol, dipyridamole, ticlopidine, beraprost, iloprost, naftidrofuryl, and statins, Dr.
Key words: Pulmonary arterial hypertension, prostacylin, epoprostenol, treprostonil, iloprost, beraprost
(TSE: 4503) today announced that Toray has obtained marketing approval for its oral PGI2 derivative prolonged release, Careload(R) LA Tablets 60mu/g (generic name: beraprost sodium), to be indicated for pulmonary arterial hypertension (PAH) on October 19,2007.